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Available online 15 February 2007Summary Treatment of the clinical N0 neck in squamous cell carcinoma (SCC) of oral cavity
and oropharynx remains a dilemma. None of the current imaging modalities are able to detect
the presence of micrometastases in the lymph nodes of clinical N0 necks reliably. The aim of
this study was to determine the diagnostic properties of fluorine-18 fluorodeoxyglucose posi-
tron emission tomography (FDG PET) in patients clinically staged as N0. FDG PET results of
38 patients were compared to histologic specimens obtained with neck dissections or to fol-
low-up. FDG PET performance was compared to computed tomography (CT), magnetic reso-
nance imaging (MRI) or ultrasonography-guided fine needle aspiration cytology (USgFNAC).
Sensitivity and specificity of FDG PET in detecting occult cervical metastases were 50% and
97% respectively. Although FDG PET performed better than conventional imaging modalities,
sensitivity was lower than desired. As a consequence, clinical application of FDG PET in the
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Table 1 Localization and pathological stage of the 38
tumors
T1 T2 T3 T4
Oral tongue 7 6 3
Gum 2 1 4
Floor of mouth 6 1 3
Base of tongue 2
Tonsillar fossa 2 1
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The presence of cervical lymph node metastases at the time
of diagnosis of squamous cell carcinoma (SCC) of the upper
aerodigestive tract has a great impact on patient’s treat-
ment and prognosis.1,2 In planning treatment, staging of
the neck is essential. It is important to distinguish between
a N0 and a N+ neck. The common diagnostic procedures for
cervical lymph node staging are clinical examination, com-
puter tomography (CT), magnetic resonance imaging (MRI)
and ultrasonography (US) with ultrasound-guided fine-nee-
dle aspiration cytology (USgFNAC) on indication. Unfortu-
nately a diagnosed N0-neck is still at risk of harboring
occult cervical lymph node metastases. Prevalences of oc-
cult spread range from 12% to 50%, basically depending on
the location and the size of the primary tumor.3–5 Although
CT and MRI of the neck have proven to be superior to palpa-
tion in detecting cervical metastases, these modalities still
have low accuracy for confirming the N0-neck. Between 40%
and 60% of all occult metastases are found using either CT or
MRI at the cost of a relatively high rate of false positives.6 In
contrast, USgFNAC has a higher sensitivity and specificity
and is more cost-effective than CT and MRI. In experienced
hands, the sensitivity for the N0 neck can reach 73% with a
specificity of 100%,7 although others reported sensitivities
ranging from 42% to 50%.8,9
Because of the risk of occult cervical metastases in a
diagnosed N0-neck in oral and oropharyngeal SCC the best
treatment still is a dilemma. In cases of a N0 neck with a
low risk for occult metastases watchful waiting is accept-
able. However, if there is a high risk for occult cervical
metastases an elective neck dissection is usually performed.
A generally accepted maximal risk for subclinical disease in
which case a watchful waiting policy is followed is 20%.10
In recent years positron emission tomography (PET) with
2-(F18)-fluoro-2-deoxy-D-glucose (FDG) has become an addi-
tional tool in the staging of head and neck cancer. In compar-
isonwith CT andMRI, FDGPET seems to be the procedurewith
the highest sensitivity and specificity for detecting lymph
node metastases of head and neck cancer.11
Aim of this study was to determine the diagnostic prop-
erties of FDG PET in patients clinically staged as N0 com-
pared to routine work-up consisting of MRI, CT and
USgFNAC.
Materials and methods
All patients with a newly diagnosed SCC of the oral cavity or
oropharynx without signs of cervical lymph node metastasis
in the physical examination (clinical N0-neck) who under-
went FDG PET scanning from December 1999 till December
2003 were selected from medical records (n = 44). The PET
scan was acquired for staging purposes before onset of
treatment. Squamous cell carcinoma was histologically con-
firmed before patients were referred for FDG PET scanning.
Five patients without neck dissection who underwent elec-
tive radiation therapy of the neck were excluded for they
could not be evaluated reliably during follow-up because
of the previous neck treatment. Another patient was ex-
cluded because of loss of the FDG PET results. In total 38 pa-
tients were included.Patients were referred for whole body FDG PET by the
Departments of Maxillofacial Surgery and Oto-Rhino-Laryn-
gology. The scans were acquired on two cameras: a Siemens
CTI ECAT 951 (31 planes over 11.8 cm) and a Siemens CTI
ECAT EXACT HR + (63 planes over 15.5 cm). The resolutions
of the systems are 6 mm full width at half maximum tran-
saxially in the center of the field of view, and 5 mm respec-
tively. The patients fasted for at least 4 h before receiving
the intravenous administration of FDG. Each patient re-
ceived five megabecquerel of FDG per kilogram. The time
interval between intravenous FDG injection and PET-imag-
ing was 90 min. An experienced nuclear medicine physician
interpreted the scan results by visual evaluation. Standard
uptake value (SUV) calculations were not performed. Be-
sides staging the neck, the FDG PET whole body scan was
also evaluated in detecting distant metastases or second
primary tumors. At the time of FDG PET imaging no patient
had clinical evidence of distant metastases or second pri-
mary tumors.
Next to FDG PET each patient underwent conventional
imaging consisting of CT (n = 19), MRI (n = 10) or US with fine
needle aspiration cytology (n = 5) or US without (n = 4) fine
needle aspiration cytology.
The results of FDG PET and the conventional imaging
modalities were obtained by studying the radiological and
nuclear medicine reports. The FDG PET and conventional
imaging modality results were compared to the histology
of the neck specimens obtained during neck dissection. His-
topathological examination of the lymph nodes was per-
formed on hematoxylin-eosin stained slides. The lymph
node was cut in one or more slices, depending on the size
of the lymph node, and completely embedded. If no neck
dissection was performed, the results were compared to
the results of clinical follow-up with a minimum of 1.5
years.
Sensitivity, specificity, accuracy, positive predictive va-
lue and negative predictive value of FDG PET and the con-
ventional imaging modalities were calculated.
Results
Primary tumor
The study group consisted of 38 patients, 17 females and 21
males with a median age of 59 (IQR 53, 68) years. Tumor
stage and localization are shown in Table 1.
FDG PET did detect the squamous cell carcinoma at the
primary site in 36 patients (sensitivity of 95%). The two tu-
mors not detected by FDG PET were superficial T1 tumors
localized in the floor of the mouth.
Table 3 Results of conventional imaging techniques in
diagnosing occult cervical metastases compared with FDG
PET for each modality separately
Occult cervical metastases
Present Absent Total
CT (n = 19)
CT+ 2 7 9
CT 1 9 10
Total 3 16 19
FDG PET+ 1 1 2
FDG PET 2 15 17
Total 3 16 19
MRI (n = 10)
MRI+ 2 2 4
MRI 2 4 6
Total 4 6 10
FDG PET+ 2 0 2
FDG PET 2 6 8
Total 4 6 10
US(gFNAC) (n = 9)
US(gFNAC)+ 0 0 0
US(gFNAC) 1 8 9
Total 1 8 9
FDG PET+ 1 0 1
FDG PET 0 8 8
Total 1 8 9
CT – computed tomography, MRI – magnetic resonance imaging,
US(gFNAC) – ultrasound(-guided fine-needle aspiration cytol-
ogy), FDG PET – fluorine-18 fluorodeoxyglucose positron emis-
sion tomography.
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In 30 patients a neck dissection was performed with a median
of 8 (IQR 2, 20) days after the PET study. The eight patients
without neck dissection had a median follow-up of 3.8 (IQR
1.7, 4.1) years. There was evidence of a positive neck on his-
tology in seven patients and by follow-up in one patient. The
prevalence of occult cervical metastases was 21% (8/38) in
this study-population. FDG PET detected cervical metastases
infivepatients. Fourof thesefive scanswere truepositive,one
was falsepositive. PETscanswerenegative forcervicalmetas-
tases in 33 patients, 29 of them showed indeed no evidence of
diseasebyhistologyor follow-up. In theother four patients, all
in the dissection group, FDG PETwas false negative (Table 2).
The cervical metastases detected by FDG PET varied in size
from4 to 7 mm.The sizes of the non-detected cervicalmetas-
tases were respectively 1 mm, 7 mm, 9 mm and 15 mm.
Because FDG PET recognized four of the eight patients
with occult cervical metastases the prevalence of occult
cervical metastases in this study decreased from 21% to
11% (4/38). As patients with a T1 tumor are often subjected
to a watchful waiting protocol, while patients with a T2 or
higher tumor stage are subjected to elective treatment of
the neck, the impact of FDG PET on prevalence of occult
cervical metastases of these two groups was assessed. The
results revealed that in T1 (n = 15) and T2–T4 patients
(n = 23) the prevalence of occult cervical metastases de-
creased from 13% (2/15) to 7% (1/15) and from 26% (6/23)
to 13% (3/23), respectively.
The diagnostic properties of the conventional imaging
methods are presented in Table 2. Table 3 shows the results
of each conventional imaging technique separately. CT
(n = 19) detected one occult cervical metastasis more with
six more false positive results comparing to FDG PET. MRI
(n = 10) detection rate was identical to FDG PET but MRI
showed two more false positive results. In the group of
US(gFNAC) (n = 9) the one patient with an occult cervical
metastasis was only detected by FDG PET, US(gFNAC)
showed no false positive results.
Distant metastases and second primary tumors
In this patient population no distant metastases were seen.
In three patients a second primary tumor was found. FDGTable 2 Diagnostic value of FDG PET and the conventional imagin
N0-neck in SCC of the oral cavity and oropharynx
Occult cervical metastases
Present Absent Total
FDG PET+ 4 1 5
FDG PET 4 29 33
Total 8 30 38
Conventional+ 4 9 13
Conventional 4 21 25
Total 8 30 38
Total population n = 38. FDG PET – fluorine-18 fluorodeoxyglucose po
methods consisting of computed tomography, magnetic resonance im
positive predictive value, NPV – negative predictive value, LR – positPET discovered two of these exclusively: an esophageal car-
cinoma and a bronchial carcinoma. Due to this detection,
these two patients could receive treatment with curative in-
tent. The third patient had a superficial T1 second primary
tumor of the tongue, which was discovered by examination
under general anesthesia. Three times FDG PET was false
positive for a second primary tumor or distant metastases.g methods in the detection of occult cervical metastases in the
Sensitivity 50% (CI: 21.5–78.5); PPV 80% (CI: 37.6–96.4)
Specificity 97% (CI: 83.3–99.4); NPV 88% (CI: 72.7–95.2)
Accuracy 87% (CI: 0.73–0.94); LR 15 (CI: 2.5–91.3)
Sensitivity 50% (CI: 21.5–78.5); PPV 31% (CI: 12.7–57.6)
Specificity 70% (CI: 52.1–83.3); NPV 84% (CI: 56.4–93.6)
Accuracy 66% (CI: 0.50–0.79); LR 1.7 (CI: 0.6–3.7)
sitron emission tomography, conventional – conventional imaging
aging or ultrasound-guided fine-needle aspiration cytology, PPV –
ive likelihood ratio, CI – 95% confidence interval.
34 C.A. Krabbe et al.Discussion
Despite advances in imaging technology, none of the current
imaging modalities is able to detect the presence of
micrometastases in the lymph nodes of clinical N0 necks
reliably. In the current study FDG PET and conventional
imaging methods separately detected four of the eight pa-
tients with occult cervical metastases. Two patients were
detected by both FDG PET and conventional imaging meth-
ods. Of the four metastases that were not detected by FDG
PET one metastasis had a diameter of 1 mm which is far be-
yond the resolution of FDG PET. The 7 mm and 9 mm cervi-
cal metastases were probably not detected because of a
high blood sugar level (7.7 mm/L) and high FDG uptake by
the muscles in the neck region, respectively, factors that
lower the contrast ratio between tumor and background.
The undetected cervical metastasis of 15 mm was in clinical
setting confused with nonspecific activity of the parotid
gland, though by reviewing clearly outlined as a hotspot
indicating metastasis.
FDG PET has a higher specificity, positive and negative
predictive value and accuracy in comparison to the conven-
tional methods (Table 2). The difference is predominantly
determined by one false-positive result by FDG PET and nine
false positive results by the conventional methods (CT and
MRI). Although there is no difference in sensitivity for both
techniques, the positive likelihood ratio differs consider-
ably: 15 for FDG PET and for the conventional methods
1.7. Because of the lower positive likelihood ratio the con-
ventional imaging methods could lead to higher numbers of
overtreatment compared with patients who were diagnosed
by FDG PET.
The accuracy of CT and MRI for nodal assessment is to a
great extent restricted by the criteria used for lymph node
metastasis. Criteria which result in a higher sensitivity sub-
sequently will lead to a lower specificity and vice versa.
While CT and MRI detect changes of morphology, structure
and of diameter, FDG PET reveals the changes in cell metab-
olism and therefore is not dependent on criteria used.
USgFNAC performed better than CT and MRI in specific-
ity, because it is very unlikely to have a false positive result.
There was only one false negative result of USgFNAC, which
was detected by FDG PET. This false negative result is in
accordance with the finding that approximately 20% of the
patients with negative USgFNAC at the time of presentation
developed a neck node metastasis during follow-up.12
In most studies in which FDG PET is compared to the con-
ventional imaging modalities FDG PET seems to be superior
for accurate staging of the neck.11,13 The role of FDG PET in
patients staged as N0 is less clear. In two studies FDG PET
performed better than conventional imaging techniques in
the N0 neck.14,15 One study found a better performance
by the conventional imaging methods probably because of
simultaneous use of more than one conventional imaging
modality in most patients which resulted in a higher overall
sensitivity.16
Because of the risk of occult metastases, the treatment
of the clinical N0-neck in squamous cell carcinoma of the
head and neck remains controversial. A generally accepted
concept is to apply a watchful waiting when the risk of oc-
cult cervical metastases is estimated to be 20% or less.10 Inthis study the addition of FDG PET to clinical investigation
reduced the risk of occult cervical metastases in the clinical
negative neck from 21% to 11%. The negative predictive va-
lue of FDG PET was 88% which implies that a patient with a
negative PET scan has a risk of occult metastases below the
threshold of 20%. In practice, the threshold of 20% would
imply that most patients with tumors staged as T2 or larger
should undergo some form of elective treatment, inevitably
leading to excess treatment in most patients. In this study
the prevalence of occult metastases was 26% in the T2–T4
group. As shown, FDG PET decreased the risk of occult
metastases in the T2–T4 group to 13%. The negative predic-
tive value was 84%. Three other studies also found a nega-
tive predictive value above 80%.14,16,17 This could suggest
that this T2–T4 group might be suitable for a watchful wait-
ing policy in case of a negative PET scan. However, due to
the low prevalence of cervical metastases in this population
a relatively high number of true negative results is expected
which will result in a higher specificity and negative predic-
tive value. As a consequence, because of this possible bias,
it is yet not appropriate to conclude that a negative FDG
PET scan could be suitable for watchful waiting policy in
the N0 neck.
Only a limited number of FDG PET studies in head and
neck cancer patients with a clinically negative neck have
been reported.14–22 These studies show different sensitivi-
ties for the detection of occult cervical metastases by
FDG PET ranging from 0% to 100% (Fig. 1). The specificities
in these studies differ in a less broad range: 76–100%. We
found a specificity of 97% due to one false-positive result.
The broad range in sensitivities found in the above men-
tioned studies can be explained by the use of different re-
search methods such as sample size, definition of N0-neck,
gold standard, and administration of FDG.
Overall the study samples were small (range n = 11–31)
which leads to broad confidence intervals.
The most important inclusion criterion used in all studies
is the clinically negative neck. This is not a clearly defined
term.23 In this study as well as in three other studies,14–16
the N0 neck was determined by physical examination (pal-
pation) only. In the other five studies the clinically negative
neck was defined by both physical examination and radio-
logical investigation17–21 The two different definitions of a
N0-neck used by these studies resulted in high and low sen-
sitivities respectively, with the exception of the FDG PET/
CT study.17 In the current study the sensitivity would have
dropped from 50% to 33% if the results of CT scanning had
been used in the definition of a clinically N0-neck.
The histopathological examinations of neck dissections in
all mentioned studies are used as the gold standard for com-
parison with FDG PET results. Different histopathological
methods may cause different sensitivities. If the lymph
nodes of a neck dissection are examined in more detail,
more occult metastases are found.3,24–26 Studies in which
lower sensitivities were found18–20 used step sectioning
and immunohistochemistry as part of histopathological
work-up.
Other factors to influence the sensitivity are the PET
camera used and the means of administration of FDG. The
PET cameras used in the above mentioned studies are dif-
ferent in brand, type and resolution. The time interval be-
tween intravenous FDG injection and PET imaging































































































Figure 1 Sensitivity of FDG PET with CI 95% in detecting occult cervical metastases in the N0-neck in different studies.
FDG PET in N0 neck 35coincides with the uptake of FDG by tumor. Delineation of
metastases from normal tissue background is important. A
greater time interval improves image contrast and thus tu-
mor detectability.27–29 An uptake period of 90 min is appro-
priate for performing clinical static PET imaging of primary
head and neck cancer.30,31 Especially in detecting microme-
tastases the tumor-to-background ratio is important. In the
studies mentioned above PET acquisition was about 60 min
or less after intravenous injection of FDG and this may not
be enough to detect occult metastases adequately.
Considering all the differences in study methods it is not
surprising that sensitivities differ in a broad range. Camera
development and the use of other tracers than FDG might
improve the diagnostic properties of PET in the N0 neck. Be-
cause of combining two modalities FDG PET/CT might find
higher sensitivities.
From this study, it is concluded that, although FDG PET
seems to have the best accuracy for detecting occult cervi-
cal metastases in the clinical N0 neck in SCC of the oral cav-
ity and oropharynx when compared to other imaging
techniques, the sensitivity is still lower than desired.References
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